Two Sigma Investments, LP Fate Therapeutics Inc Transaction History

Two Sigma Investments, LP

$42.3 Billion
Q3 2024

A detailed history of Two Sigma Investments, LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 459,565 shares of FATE stock, worth $744,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares

459,565

Previous 1,019,987 54.94%

Holding current value

$744,495

Previous $3.35 Million 51.93%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $1.75 Million - $3.12 Million	-560,422 Reduced 54.94%	459,565 $1.61 Million
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $2.46 Million - $5.35 Million	754,987 Added 284.9%	1,019,987 $3.35 Million
Q1 2024 May 15, 2024	SELL	$3.54 - $8.35 $4.55 Million - $10.7 Million	-1,285,659 Reduced 82.91%	265,000 $1.95 Million
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $166,011 - $396,415	-100,613 Reduced 6.09%	1,550,659 $5.8 Million
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $537,871 - $1.34 Million	-266,273 Reduced 13.89%	1,651,272 $3.5 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $544,839 - $754,304	114,462 Added 6.35%	1,917,545 $9.13 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $1.27 Million - $3.33 Million	299,333 Added 19.91%	1,803,083 $10.3 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $13 Million - $31.3 Million	1,314,683 Added 695.35%	1,503,750 $15.2 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $3.98 Million - $6.82 Million	189,067 New	189,067 $4.24 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $436,149 - $886,116	-14,700 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $13.6 Million - $18.3 Million	-284,842 Reduced 95.09%	14,700 $860,000
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $383,299 - $619,085	6,467 Added 2.21%	299,542 $17.8 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $24.6 Million - $33.9 Million	-366,508 Reduced 55.57%	293,075 $25.4 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $24.3 Million - $39.6 Million	337,241 Added 104.62%	659,583 $54.4 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $1.77 Million - $4.7 Million	-46,582 Reduced 12.63%	322,342 $29.3 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $4.62 Million - $6.15 Million	151,961 Added 70.04%	368,924 $14.7 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $4.38 Million - $7.64 Million	216,963 New	216,963 $7.44 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $457,608 - $844,246	-26,482 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $572,275 - $885,979	-42,739 Reduced 61.74%	26,482 $518,000
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $1.07 Million - $1.56 Million	69,221 New	69,221 $1.08 Million
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $2.77 Million - $3.63 Million	-177,404 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$13.15 - $18.71 $1.98 Million - $2.82 Million	-150,471 Reduced 45.89%	177,404 $3.12 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $1.54 Million - $2.28 Million	-134,494 Reduced 29.09%	327,875 $4.21 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $4.05 Million - $7.53 Million	462,369 New	462,369 $7.53 Million
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $830,848 - $1.22 Million	-90,704 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $503,571 - $1.1 Million	-79,932 Reduced 46.84%	90,704 $885,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $672,305 - $1.13 Million	170,636	170,636 $1.04 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $157M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Fate Therapeutics Inc Transaction History